Utilizing RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform), the companies hope to enhance the treatment of difficult-to-access tumors.
“Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally advanced disease to treating metastatic disease with immunotherapy,” said Shaun Bagai, CEO of RenovoRx. “We look forward to combining our proprietary TAMP platform with Imugene’s CF33 oncolytic virus with the goal of optimizing clinical benefits for patients.”
As part of the collaboration, the companies plan to investigate the administration of the CF33 technology with TAMP. This could provide the ability to treat tumors like those in pancreatic and liver cancers. Delivering CF33 trans-arterially may improve upon traditional methods that limit therapy uptake. Traditional options often struggle through dense fibrous tissues and the lack of blood vessels supplying the tumors.
RenovoRx designed TAMP to ensure the precise delivery of therapeutics to a target tissue. The company says this unique approach could potentially increase an oncology therapy’s efficacy and improve safety. It could also widen the therapy’s therapeutic window by focusing its distribution uniformly in target tissue.
“We believe the synergy between RenovoRx’s trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients,” said Leslie Chong, managing director & CEO of Imugene.
